

SINO BIOPHARMACEUTICAL LIMITED

(THE “COMPANY”)

BOARD DIVERSITY POLICY

This Board Diversity Policy (the “Policy”) sets out the approach for achieving diversity on the board of directors (the “Board”) of the Company, including but not limited to the appropriate balance of skills, experience and diversity of perspectives that are required to support the attainment of the Company’s strategic objectives and its sustainable development. It has been established in light of the fact that increasing emphasis on diversity has been viewed as a component for wider and more comprehensive corporate governance framework.

A. Approval of Policy

This policy has been approved and adopted by the Board of Directors of the Company on 30 August, 2013.

B. Policy Statement

The Company recognizes and embraces the importance and benefits of having a diverse Board, and sees the increasing diversity at the Board level as one of the crucial elements in supporting the attainment of the Company’s overall strategic objectives and its expansion and development.

C. Measurable Objectives

The Nomination Committee of the Company may make recommendations to the Board for identifying the necessary criteria when considering appointment of new directors of the Company. Selection of appropriate candidates will be based on a range of diversity perspectives, including but not limited to gender, age, race, ethnicity, cultural and educational background, professional experience, skills, knowledge and length of service. The ultimate decision will be based on the anticipated merit and contribution that the selected candidate will bring to the Board. The composition of the Board will be

disclosed in the annual Corporate Governance Report and the interim report.

The target proportion of independent non-executive directors among board members shall be no less than one-third.

D. Monitoring and Disclosure of the Policy

The Nomination Committee of the Company shall monitor the policy from time to time and make the necessary adjustments such that it best suits the needs of the Company. It will also monitor the implementation of the policy to ensure its continued effectiveness.

This Policy or a summary of this Policy will be disclosed, where appropriate.

E. On-going Review of the Policy

The Nomination Committee will review this Policy from time to time and the necessary procedures from time to time according to the latest regulatory requirements, then for review and approval by the Board.